Clinical Trial Update: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results for the combination of 9-ING-41, retifanlimab, gemcitabine, and nab-paclitaxel in advanced pancreatic adenocarcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 9-ING-41
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Anwaar Saeed | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-07-17